Lenzing's August 25 Showdown: A Doubled Bottom Line Meets a €300m Shareholder Decision
Published on 08/08/2026 at 16:43 | Redaktion boerse-global.de
The arithmetic at Lenzing is getting harder to ignore. Austria's fibre maker has just posted a first-half net profit that more than doubled year-on-year, yet the share price sits nearly a fifth below its June peak, and the company is asking shareholders to approve a capital increase that will test their patience with dilution.
The numbers tell a story of operational progress wrapped in financial strain. Net income for the first half of 2026 climbed to €35.6 million from €15.2 million in the prior-year period, but revenue slipped to €1.27 billion from €1.34 billion. EBITDA eased to €239.2 million from €268.6 million, leaving the margin at 18.9 percent — short of the company's own 20-to-25 percent target corridor. The per-share loss narrowed to €0.09 from €0.90.
A Profit That Isn't What It Seems
Investors would be wise to look beneath the headline earnings figure. The secondary source notes that the profit jump was driven primarily by foreign-exchange effects and an improved financial result, not by the underlying business. That distinction matters as the company pursues its "Grow Nonwovens, Reset Textiles" strategy — a plan to expand the hygiene-focused nonwovens division while shrinking textiles' share of revenue from roughly 45 percent to about 30 percent over the medium term.
There are genuine signs of operational recovery. Fibre selling prices rose 6 percent in the second quarter, and pulp costs climbed to $850 per tonne from $780, with Lenzing guiding toward approximately $900 for the third quarter. Operating EBITDA for the second quarter exceeded €100 million excluding one-off items, up 9 percent year-on-year. The cost-cutting programme targeting €120 million in savings has already delivered €25 million.
Should investors sell immediately? Or is it worth buying Lenzing?
Yet the cost side remains a drag. Caustic soda is eating more than €10 million per month, sulphur less than €5 million, and while management doesn't expect a sharp deterioration in the third quarter, these inputs continue to pressure margins.
The Balance Sheet Squeeze
The financial picture is where the tension builds. Operating cash flow reached €160.4 million in the first half, but free cash flow came in at just €45.8 million — a gap explained by elevated investment spending. Lenzing plans roughly €150 million in capital expenditure for the full year, and that outlay is visible in the leverage metrics: net debt to EBITDA has risen to 3.6 times from 3.3 times at the end of 2025.
This is the backdrop against which the extraordinary general meeting on August 25 takes on outsized significance. Shareholders will vote on a capital increase with subscription rights of up to €300 million — the centrepiece of a €600 million refinancing package that also includes new financing agreements of up to €300 million and an extension of existing liabilities through 2030.
The financing appears largely secured in practice. Anchor shareholders B&C Group and Suzano, which together control roughly 52.25 percent of the capital, have committed €156.7 million. Oberbank, holding 3.86 percent, has pledged about €11.6 million. A banking consortium guarantees the remainder. But the formal approval still rests with shareholders, who will decide on the scope and terms.
The Dilution Dilemma
For existing investors, the capital increase cuts both ways. A €300 million raise against a current market capitalisation of roughly €907.5 million represents a meaningful shift in the ownership structure, even with subscription rights attached. The company is targeting a leverage ratio below 2.5 times and hopes the cost programme will drive margins back into the 20-to-25 percent range by the end of 2027.
Beyond dilution, several risks loom. Impairment charges on fixed assets of up to €150 million are possible in 2026 — non-cash and EBITDA-neutral, but a significant hit to EBIT and group results. Restructuring provisions of up to €40 million will weigh directly on this year's EBITDA. The planned closure of the Heiligenkreuz site in Austria by the end of 2026 and the Grimsby plant in England by the end of 2027 — part of a global reduction of around 2,000 of the 7,700 full-time positions — carry political as well as operational risk. Burgenland's governor Hans Peter Doskozil has not ruled out the state taking over Heiligenkreuz if no private buyer emerges, a sign that the divestment process is far from straightforward.
Lenzing at a turning point? This analysis reveals what investors need to know now.
A Market That's Not Yet Convinced
The share price reaction to the results was telling. On Friday, Lenzing closed at €23.85, down 2.85 percent on the day, leaving the stock almost 20 percent below its 52-week high of €29.75 reached in June. The seven-day picture shows a modest gain of 1.49 percent, but the monthly view is a decline of roughly 5 percent.
Long-term shareholders have endured far worse. Over the past decade, the stock has lost an average of 16 percent per year — an investment of €10,000 would now be worth approximately €2,501. That history explains the caution surrounding the current turnaround narrative.
The August 25 meeting will likely settle the financing question — the anchor shareholders and banking consortium have effectively removed the risk of failure. What remains uncertain is whether the strategic pivot can deliver the margin recovery management promises, and whether the textile demand softness visible in the first-half revenue decline is cyclical or structural. If the nonwovens growth can't fully offset the textiles retreat, the restructuring may prove longer and costlier than the current plan suggests.
Ad
Lenzing Stock: New Analysis - 8 August
Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
